Gain a deeper understanding of the impact of Idiopathic Pulmonary Fibrosis (IPF) in Australia. Join Lung Foundation Australia, Prof. Haydn Walters, Dr Ingrid Cox and Dr Qiang Zheng as they provide an overview of the University of Tasmania’s research into the epidemiology of IPF, including key statistics and the impact of IPF in Australia.
The webinar explores research into the epidemiology of IPF, including incidence, prevalence, mortality, and survival rates, and the economic aspects like quality of life, costs, and predictive models. Globally, most IPF studies come from the USA and Europe, showing varied estimates due to different methods or actual differences. In Australia, data on IPF distribution is limited. Using available data, the study analysed mortality and survival rates, finding an average of 10 new IPF cases per 100,000 people annually. Improved diagnostic criteria and treatments have slightly decreased new cases and mortality rates.
The webinar explores the survival rates and global mortality trends, likely due to aging populations and poor air quality. The average age at diagnosis has risen, with a diagnostic delay of around 20 months. Early GP visits, specific clinical guidelines, and diagnostic biomarkers can reduce this delay. Survival rates improved after 2010, possibly due to better management and anti-fibrotic treatments. Risk factors include age, gender, and genetics, while modifiable factors like smoking and air quality also play roles. Protective factors include antibiotic treatments and lung transplants.
The study revealed varied disease severity among participants, impacting overall quality of life. IPF patients had similar quality of life to those with COPD, angina, and uncomplicated stroke, but worse than those with bronchitis, chronic kidney failure, and uncomplicated lung cancer. Factors like multiple comorbidities and declining lung function further decreased quality of life. Pharmaceutical costs, particularly for anti-fibrotic medications, were significant, with a notable increase in prescriptions since government subsidisation in 2017. Future research will explore geographic trends, prescribing practices, and the impact of comorbidities and acute exacerbations on IPF management.
Was this page helpful?
Good job! Please give your positive feedback
How could we improve this post? Please Help us.
